STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of two drugs, ceritinib and everolimus, given together to adults with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find a dose that controls tumor growth with manageable side eff…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
Could a new drug boost lung cancer treatment?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemoradiation helps people with stage III non-small cell lung cancer that can't be surgically removed. It first finds the best dose, then compares the combination to standard treatment alone. About 53 adults particip…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:46 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has worsened after previous treatment. The main goal is to find the safest dose and understand side effects. About 36…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
Precision radiation boosts tumor attack in advanced lung cancer trial
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the dose to nearby healthy organs standard, is safe and effective for people with stage II to III non-small cell lung cancer. It uses advanced imaging to guide either photon (IMRT) or pro…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC